Mindmed appoints mgh psychiatrist-in-chief dr. maurizio fava to scientific advisory board

New york, june 23, 2021 /prnewswire/ -- mindmed (nasdaq: mnmd) (neo: mmed) (de: mmq) (the "company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of dr. maurizio fava, a world-leading expert in psychiatry and psychiatric clinical trials from massachusetts general hospital and the harvard medical school to the company's scientific advisory board. dr. fava obtained his md from the university of padova school of medicine where he completed residency training in endocrinology.
MNMD Ratings Summary
MNMD Quant Ranking